Benzinga's Volume Movers (MATK, CMED, INCY, AMED)

Martek Biosciences Corporation MATK shares moved up 35.15% to $31.57 at 10:40 am. The volume of MATK shares traded was 24348% higher than normal. Royal DSM NV announced its plans to purchase MATK for $1.09 billion, or $31.50 per share in cash, representing a 35% premium to MATK's closing price on Monday. China Medical Technologies Inc CMED shares rose 5.00% to $11.76. The volume of CMED shares traded was 1003% higher than normal. CMED's PEG ratio is 0.27. Incyte Corporation INCY shares climbed 6.39% to $16.15. The volume of INCY shares traded was 719% higher than normal. INCY reported positive top-line results for its cancer drug. Amedisys Inc AMED shares gained 8.89% to $31.83. The volume of AMED shares traded was 327% higher than normal. Analysts at Deutsche Bank upgraded AMED from “hold” to “buy.” Read more from Benzinga's Markets.